Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Climate Change Risk to MS Patients: Worse Symptoms, More Relapses

Temperature variability and increasing exposure to airborne pollutants — both consequences of climate change — can worsen disease symptoms and risk relapses in people with multiple sclerosis (MS), according to a recent review study. Unwanted effects of environmental change were also linked to a number of other neurological conditions,…

#ECTRIMS2022 – Vumerity Lowers RRMS Activity Over 2 Years

Up to two years of Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to a final analysis of data from the open-label EVOLVE-MS-1 Phase 3 clinical trial. Indirect comparisons of Vumerity-treated patients against those…

#ECTRIMS2022 – High-efficacy DMTs Linked to Cervical Cancer Risk

Exposure to high-efficacy disease-modifying therapies (DMTs) is associated with an increased risk of cervical abnormalities in women with multiple sclerosis (MS), recent data suggest. The findings are consistent with previous reports showing these treatments may raise the risk of certain cancers, likely as a consequence of their immune-modulating…

Maker of PoNS Device for MS Salutes Physical Therapists

For National Physical Therapy Month, Helius Medical Technologies is spotlighting physical therapists who make possible the success of the company’s portable neuromodulation stimulator (PONS) device to treat gait problems in people with multiple sclerosis (MS). Helius will broaden access to its free online PoNS training program by enabling…

GoodRx Offers MS Patients Digital Vumerity Enrollment Form

GoodRx, in collaboration with Biogen, has made the enrollment form for starting a multiple sclerosis (MS) patient on Vumerity (diroximel fumarate) available on its new “Provider Mode” digital platform. By adding the electronic enrollment form, the company hopes doctors will be able to prescribe their patients Vumerity more…

Second SPMS Patient Given Foralumab Continues to Improve

Six months of treatment with foralumab nasal spray led to significant functional improvements in the second patient with non-active secondary progressive multiple sclerosis (SPMS) who received treatment under a single-patient expanded access program. Findings from this patient have been generally consistent with those seen in the first non-active SPMS…